Drug · Small Molecule

Carmustine

CI-DRUG-00000144Explore in graph →NCIt C349 CHEMBL513 CIViC Approved

Regulatory

Approvals (8)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory4 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as BICNU (DIN 02555093) under ATC L01AD01 CARMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Mar 11, 2026	Apr 14, 2025	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CARMUSTINE FOR INJECTION USP (DIN 02531879) under ATC L01AD01 CARMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 18, 2023	health-canada-dpd
CA Health Canada	—	Marketed in Canada as GLIADEL WAFER (DIN 02238985) under ATC L01AD01 CARMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Market

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 13 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	14	9	36	191	8	CA, EU, US	Dec 31, 1975	1988-04
Non-Hodgkin Lymphoma	Phase3	Phase 3	6	3	8	49	0	—	—	1994-01
Malignant Breast Neoplasm	Phase3	Phase 3	1	1	2	5	0	—	—	1991-12
Malignant Central Nervous System Neoplasm	Phase3	Phase 3	1	1	4	15	0

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MGMT Promoter Methylation1
Carmustine	Glioblastoma

Clinical trials

Trials with this intervention (191)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–100 of 191 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00345865	Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma	completed	Phase 2	473	Masonic Cancer Center, University of MinnesotaOTHER	1	Jul 14, 2020	clinicaltrials
NCT00795665	Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma	completed

Molecule

Record

Kind: Small Molecule
Mechanism: Glutathione reductase inhibitor; DNA inhibitor; RNA inhibitor
Targets: 1 gene
UNII: U68WG3173Y
Aliases: 1,3-Bis(2-chloroethyl)-1-nitrosourea, 1,3-Bis(beta-chloroethyl)-1-nitrosourea, BCNU, Becenum, Becenun, Bicnu, BiCNU, Bischloroethyl nitrosourea, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Camustine, Carmubris, Carmustin, Carmustina, Carmustine, Carmustine medac, Carmustine medac (previously carmustine obvius), Carmustine obvius, Carmustinum, DTI-015, FDA 0345, FDA-0345, GLIADEL, GLIADEL WAFER, Nitrourean, Nitrumon, N,N'-Bis(2-chloroethyl)-N-nitrosourea, NSC 409962, NSC-409962, NSC409962 … (+6)

Data updated 16 hours agoSource updated unknown

Identifiers

Codes (10)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01AD01	CARMUSTINE
DIN (Health Canada)	00297763